Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56


Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.

Raguz S, Randle RA, Sharpe ER, Foekens JA, Sieuwerts AM, Meijer-van Gelder ME, Melo JV, Higgins CF, Yagüe E.

Int J Cancer. 2008 Mar 1;122(5):1058-67.


Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion.

Raguz S, Tamburo De Bella M, Tripuraneni G, Slade MJ, Higgins CF, Coombes RC, Yagüe E.

Clin Cancer Res. 2004 Apr 15;10(8):2776-83.


Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.

Punyammalee B, Manoromana S, Purisa W, Chariyalertsak S, Rerkamnuaychok B.

J Med Assoc Thai. 1997 Sep;80 Suppl 1:S162-73.


Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.

Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y.

Cancer Sci. 2006 Nov;97(11):1198-204. Epub 2006 Aug 22.


Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.

Kim HG, Hien TT, Han EH, Hwang YP, Choi JH, Kang KW, Kwon KI, Kim BH, Kim SK, Song GY, Jeong TC, Jeong HG.

Br J Pharmacol. 2011 Mar;162(5):1096-108. doi: 10.1111/j.1476-5381.2010.01101.x.


New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.

Molnar J, Mucsi I, Nacsa J, Hevér A, Gyémánt N, Ugocsai K, Hegyes P, Kiessig S, Gaal D, Lage H, Varga A.

Anticancer Res. 2004 Mar-Apr;24(2B):865-71.


Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells.

Toth M, Boros IM, Balint E.

Cancer Sci. 2012 Apr;103(4):659-69. doi: 10.1111/j.1349-7006.2012.02215.x. Epub 2012 Mar 19.


Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-κB in R-HepG2 cell line.

Sun J, Yeung CA, Co NN, Tsang TY, Yau E, Luo K, Wu P, Wa JC, Fung KP, Kwok TT, Liu F.

PLoS One. 2012;7(8):e40720. doi: 10.1371/journal.pone.0040720. Epub 2012 Aug 22.


Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil.

Ye W, Chang HL, Wang LS, Huang YW, Shu S, Dowd MK, Wan PJ, Sugimoto Y, Lin YC.

Anticancer Res. 2007 Jan-Feb;27(1A):107-16.


MDR1 gene expression in primary and advanced breast cancer.

Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, Press MF.

Lab Invest. 1999 Mar;79(3):271-80.


Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.

Dönmez Y, Gündüz U.

Biomed Pharmacother. 2011 Mar;65(2):85-9. doi: 10.1016/j.biopha.2010.12.007. Epub 2010 Dec 30.


Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.

Chevillard S, Lebeau J, Pouillart P, de Toma C, Beldjord C, Asselain B, Klijanienko J, Fourquet A, Magdelénat H, Vielh P.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2471-8.


Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein.

Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T, Hatayama T, Nakayama Y.

Biochem Biophys Res Commun. 2014 Jun 13;448(4):430-6. doi: 10.1016/j.bbrc.2014.04.125. Epub 2014 May 2.


Redundancy of biological regulation as the basis of emergence of multidrug resistance.

Shtil AA, Azare J.

Int Rev Cytol. 2005;246:1-29. Review.


MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.

Zhang X, Wu X, Li J, Sun Y, Gao P, Zhang C, Zhang H, Zhou G.

J Surg Oncol. 2011 Oct;104(5):466-71. doi: 10.1002/jso.21958. Epub 2011 May 2.


Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.

Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR.

Clin Cancer Res. 1997 Nov;3(11):2025-32.


Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.

Taheri M, Mahjoubi F, Omranipour R.

Genet Mol Res. 2010 Jan 12;9(1):34-40. doi: 10.4238/vol9-1gmr669.

Supplemental Content

Support Center